Introduction
Raltegravir is the first inhibitor of the HIV integrase approved for clinical use. The enzyme is responsible for the transfer of virally encoded DNA into the host chromosome. Raltegravir was initially approved for the treatment of HIV-infected patients failing other antiretroviral regimens and harbouring multidrug-resistant HIV variants. More recently, the drug has also been approved as firstline therapy. The registrational trials that supported the first approval of raltegravir are the BENCHMRK 1 and 2 studies. 1, 2 In these trials, the safety and efficacy of raltegravir versus placebo along with an optimized background regimen was assessed, and raltegravir outperformed the control arm. Interestingly, premature raltegravir discontinuations due to adverse events occurred in only 1.5% of patients while it was 2.5% in the placebo arm. The hepatic safety profile of raltegravir was good, with only 4.3% of treated patients experiencing grade 3 -4 hepatotoxicity, compared with 3.4% in the placebo group. However, HIVþ patients with chronic hepatitis C were minimally represented in these studies and subjects with serum aminotransferases at .5-fold the upper limit of normality (ULN) were uniformly excluded. Chronic hepatitis C virus (HCV) infection affects overall nearly one-quarter of the HIV-infected population worldwide. 3 For almost all antiretroviral drugs, the rate of liver enzyme elevations (LEEs) is uniformly greater in HIV-infected patients with underlying chronic hepatitis C compared with the rest. 4 -6 Therefore, there is a need to evaluate the hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C.
Patients and methods
A prospective, observational study of the hepatic safety profile of raltegravir was initiated in January 2006 at a reference HIV clinic in Madrid, after the beginning of the expanded access programme for raltegravir in Spain. The study was extended following the approval of raltegravir, and enrolment of patients ended in January 2009. Clinical data and laboratory parameters were recorded at baseline, week 4 and every 3 months thereafter. The study received approval by the hospital Ethics Committee and written informed consent was obtained from all participants in the study. Chronic hepatitis C was defined based on the demonstration of positive serum HCV-RNA using a commercial real-time PCR assay (Taqman, Roche, Basel, Switzerland), which has a lower limit of detection of 10 IU/mL.
Estimates of liver fibrosis in chronic hepatitis C patients were measured at baseline and every 6 months using FibroScan w (Echosens, Paris, France). This method assesses hepatic stiffness and results are given as kilopascal units (kPa). 7 There is a good correlation between liver fibrosis staging in liver biopsy and hepatic stiffness using FibroScan. 8, 9 Since liver fibrosis is the major determinant of the severity of chronic hepatitis C, its longitudinal assessment may permit cofactors to be identified, including potentially hepatotoxic drugs, acting as accelerators of liver fibrosis progression.
10,11
Standard laboratory testing included complete blood cell count, serum biochemistry, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, CD4 count and plasma HIV-RNA. The change in serum ALT and AST from pre-treatment with raltegravir to the highest level during treatment was categorized using a standardized toxicity grade scale previously reported, 12 which slightly modifies the AIDS Clinical Trials Group criteria. 13 In more detail, patients with pretreatment serum AST and ALT values within normal range (30 U/L) were classified as having hepatotoxicity based on changes relative to the ULN: grade 1, 1.25 -2.5 ULN; grade 2, 2.6-5 ULN; grade 3, 5.1-10 ULN; and grade 4, .10 ULN. To avoid selection bias favouring inclusion of persons with chronic hepatitis C, patients with elevated raltegravir pretreatment serum AST and/or ALT values (higher than the ULN) were classified based on changes relative to baseline values rather than ULN: grade 1, 1.25 -2.5 baseline; grade 2, 2.6-3.5 baseline; grade 3, 3.6-5 baseline; and grade 4, .5 baseline. If AST and ALT grades were discordant, the higher of the two was used for classification. Hepatotoxicity of any degree was considered for LEE grades 1 -4, and severe hepatotoxicity for LEE grades 3 and 4.
Statistical analyses
Descriptive values are expressed as absolute numbers and percentages, medians [interquartile range (IQR)] or means (+SD). Both groups of patients were first compared in a cross-sectional study using the x 2 test for categorical data and parametric or non-parametric tests for continuous variables, as needed. Kaplan-Meier and log rank tests were used for survival analyses. Factors associated with hepatotoxicity were examined by univariate and multivariate logistic regression models. Variables with P , 0.2 in the univariate analysis were entered into the multivariate analysis. All data were recorded and analysed using the SPSS software package v15.0 (SPSS Inc., North Chicago, IL, USA).
Results
From a total of 311 HIV-infected patients who initiated raltegravir therapy during the study period, 218 (70.1%) entered this study. Irregular attendance of visits (n ¼43), complete loss to follow-up (n¼ 17), poor drug adherence (n¼ 16), lack of informed consent (n¼ 16) and death (n¼ 3) were the reasons for exclusion of the remaining patients. In addition, eight HIV/HCV co-infected patients were excluded from this analysis because they underwent hepatitis C therapy while on raltegravir treatment.
Of the study population, 126 (58%) were HIV mono-infected and 92 (42%) were HIV/HCV co-infected patients. Table 1 displays the main baseline characteristics of the study population, according to HCV status. HIV/HCV co-infected patients were younger and had lower CD4 counts than HIV mono-infected individuals, most likely reflecting that most were former intravenous drug users while many HCV-negative patients with HIV infection had been infected through homosexual contact. The two populations did not differ significantly in any other characteristic, including antiretroviral treatment modality.
All patients included in the study were antiretroviral experienced, given that raltegravir had been approved only for this subset of patients at the time the study was conducted. Besides being part of a rescue antiretroviral intervention in patients failing a prior regimen, in this study raltegravir was prescribed in 63% of patients because of poor tolerance or side effects with an otherwise virologically suppressive regimen. Raltegravir was accompanied in 87% of cases by two nucleoside reverse transcriptase inhibitors (NRTIs), mostly tenofovir/emtricitabine (Truvada w ) or abacavir/lamivudine (Kivexa w ). Besides, ritonavir-boosted protease inhibitors (PIs) were used by 39% of subjects and nonNRTIs (NNRTIs) by 8% of patients.
The mean length of follow-up of patients treated with raltegravir was 14.1+6.1 months in HIV mono-infected subjects and 12.7+4.8 months in HIV/HCV co-infected subjects. Any degree of hepatotoxicity (grade 1 -4) occurred in 10 (7.9%) HIV mono-infected patients and 23 (25%) HIV/HCV co-infected patients [relative risk (RR) 3.1; 95% confidence interval (95% CI) 2.9-3.4; P ¼ 0.002]. The median time to any degree of hepatotoxicity was 6 months (IQR 3 -16) and 3 months (IQR 1 -6), respectively. Figure 1 shows the Kaplan -Meier curves for any degree of hepatotoxicity according to HCV co-infection status.
Only three patients developed severe hepatotoxicity (grade 3 or 4), all of which occurred in HIV/HCV co-infected individuals. In these subjects, LEEs occurred at months 1, 15 and 15, respectively. However, in all three cases reasons other than raltegravir exposure most likely explained LEEs. It was alcohol abuse (.50 g/day) in two patients and resumption of intravenous drug abuse in another. The first two subjects continued with raltegravir therapy and aminotransferases returned to normal values after stopping alcohol abuse. In the third patient, raltegravir was discontinued following virological failure as a result of poor adherence. Liver enzymes were persistently elevated during two subsequent visits 2 and 4 months later, while the patient admitted continuous intravenous drug use; he was lost to follow-up thereafter.
As a whole, in this observational study, raltegravir was discontinued in nine (4.1%) subjects; five (4%) HIV mono-infected patients and four (4.3%) HIV/HCV co-infected patients (P ¼ 0.6).
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The main reasons for raltegravir withdrawal were poor adherence (n¼5), virological failure (n ¼3) and headache (n¼ 1).
At baseline, median liver stiffness values were 5.6 and 8.0 in HIV mono-infected and HIV/HCV co-infected patients, respectively (P,0.001). Overall, no significant changes in median values occurred at 6, 12 and 18 months (data not shown). Progression of liver fibrosis from one Metavir staging estimate to the next over the 18 month study period occurred in three patients, all of them HIV/HCV co-infected. It was from F1 to F2 in two patients and from F3 to F4 in another. None of them experienced significant LEEs. Of note, only one out of six patients (all HIV/HCV co-infected) with liver cirrhosis at baseline experienced grade 2 LEEs.
In the univariate analysis, hepatotoxicity of any degree (grade 1 -4) was significantly associated with HCV infection (P ¼0.002), elevated baseline AST (P ¼ 0.03), elevated baseline ALT (P ¼ 0.04) and baseline advanced liver fibrosis (P ¼ 0.02) ( Table 2 ). The rate of LEEs did not differ according to baseline body mass index (BMI), CD4 count, plasma HIV-RNA, gender or age. The multivariate analysis (RR, 95% CI, P) revealed HCV co-infection as the only independent variable associated with any degree of hepatotoxicity (RR 2.9; 95% CI 2.3-3.3; P ¼ 0.03).
In order to provide a proper view of the hepatic safety profile of raltegravir with respect to other antiretroviral agents, we carried out a similar analysis for patients that consecutively began regimens based on PIs or NNRTIs at our institution during the same period. The most common PIs used were atazanavir (53%), lopinavir (46%) and darunavir (1%), while the most common NNRTIs were efavirenz (67%) and nevirapine (33%). In all cases, except for half of the patients on atazanavir, PIs were used with low-dose ritonavir as a booster. All these drugs were taken in the majority of cases along with two NRTIs, Truvada w and Kivexa w being the most common. Figure 2 displays the rate of LLEs over the first 12 months of therapy using all these regimens.
Discussion
Hepatotoxicity is a potentially serious complication of HIV treatment and elevation of serum aminotransferases is often the first sign of antiretroviral-associated liver injury. 4 The rate of hepatotoxicity varies widely, depending mainly on antiretroviral drugs used and the prevalence of chronic hepatitis C in the study population. In the largest studies, significant liver toxicity has ranged from 8% to 18%. 5,6,14 -19 The contribution of underlying chronic hepatitis C to the increased risk of LEEs following initiation of any antiretroviral regimen has been further confirmed by studies that have shown a reduction in the risk of hepatotoxicity 20, 21 In our study the rate of any degree of LEEs and/or severe LEEs in patients treated with raltegravir was within the expected range for other antiretroviral agents that are considered as safe in terms of hepatic safety profile. 4 As expected, LEEs occurred more frequently in patients with chronic hepatitis C than in the rest (3-fold on average). All episodes of LEEs were mild (grade 1 -2) with no cases of severe hepatotoxicity attributed to raltegravir. Moreover, none of the patients discontinued raltegravir due to LEEs. Lastly, only one of the six baseline cirrhotic HIV/HCV co-infected patients treated with raltegravir experienced grade 2 LEEs. This observation is important given that the risk of drug-related liver toxicity is particularly increased in the subset of co-infected patients with liver cirrhosis. 22 Fluctuations in liver enzymes are common in patients with chronic hepatitis C 3 and certainly might have contributed to recognition of mild LEEs in HIV/HCV co-infected patients who received raltegravir, and in this way contribute to overestimating a potential raltegravir-associated hepatotoxicity. On the other hand, in both HIV mono-infected and HIV/HCV co-infected patients, antiretroviral agents prescribed along with raltegravir could account for some LEE episodes. 4,14 -19 Just for comparison purposes, studies that have assessed the incidence of hepatotoxicity in patients exposed to a well-known hepatotoxic agent, such as nevirapine, have reported rates of 12% -16% for grade 3 -4 LEEs. 5, 6 In the control group examined in our study, LEEs over the first 12 months of therapy occurred more frequently with PIs and NNRTIs than with raltegravir, although the retrospective observational nature of the study and the heterogeneity of the patient populations precluded more definitive conclusions from being drawn.
Finally, the lack of recognition of any significant progression of liver fibrosis in HIV/HCV co-infected patients treated with raltegravir during the study period is reassuring in terms of the hepatic safety profile of the drug. It should be noted, however, that the mean follow-up was relatively short (12 months), and hepatic fibrosis estimates were obtained using elastometry. Altogether our results demonstrate the hepatic safety profile of raltegravir in HIV-infected patients, including those with chronic hepatitis C.
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